Retatrutide: results, approval status and availability

What did the latest trials show?

Lilly’s July 2026 announcement reported average weight reductions of up to 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3 at 80 weeks under the efficacy estimand. The trials enrolled different populations: adults with type 2 diabetes and excess weight, and adults with severe obesity and established cardiovascular disease. Gastrointestinal side effects were common, and some participants stopped treatment because of adverse events. Read Lilly’s results and study details.

These are company-reported trial averages, not predictions for an individual. They do not establish that a product sold online under the same name has the trial medicine’s identity, quality or effects.

When could it become available?

In that announcement, Lilly said it planned a U.S. regulatory submission in the first quarter of 2027. A planned submission is not an approval date. Review, approval and commercial availability are separate steps, so there is no confirmed launch date to promise.

Can a pharmacy compound retatrutide now?

FDA states that retatrutide cannot be used in compounding under federal law. The agency also warns about unapproved products marketed to consumers as research materials. A “research use” label does not make a product an appropriate treatment. Read FDA’s current guidance.

What can you consider today?

A weight-management consultation can compare currently available treatments, your health history and what you want to achieve. Semaglutide and tirzepatide are different medicines from retatrutide; the preparations offered through AnthologyRX are compounded and are not FDA-approved finished products. Our comparison explains the relevant evidence and product distinctions.